[Enhancement of therapeutic efficacy of aclarubicin against lymph node metastases using a new dosage form: aclarubicin adsorbed on activated carbon particles].
Seven days after a subcutaneous inoculation of 5 x 10(5) P388 leukemia cells into the foot pad of the left hind paw of donor mouse, aclarubicin (0.2mg/kg body weight) was injected subcutaneously into the hind paw of the opposite foot pad in the form of ACR-CH or aclarubicin aqueous solution. On day 10, the left popliteal and the lower para-aortic lymph nodes taken from each donor were transferred intraperitoneally to a normal recipient mouse. The combined survival time of recipients and the viable P388 leukemia cell number in popliteal and para-aortic lymph nodes were estimated with a calibration formula. Our results showed that the survival curve of recipients given ACR-CH was statistically improved compared with that of other treatment groups.
Sakakura
C
C
First Dept. of Surgery, Kyoto Prefectural University of Medicine.
Takahashi
T
T
Sawai
K
K
Hagiwara
A
A
Shimotsuma
M
M
Shobayashi
S
S
Ozaki
K
K
Sasaki
S
S
Tsujimoto
H
H
Shirasu
M
M
D015250:Aclarubicin / Q000008:administration & dosage*; D000818:Animals; D002244:Carbon / Q000008:administration & dosage; D016503:Drug Delivery Systems; D007941:Leukemia P388 / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000517:prevention & control*; D051379:Mice; D011205:Povidone / Q000008:administration & dosage
D002244:Carbon; D015250:Aclarubicin; D011205:Povidone